Answers are grounded in this paper and cite their sources.
Investigates combination therapy's impact on cholestatic liver fibrosis, suggesting new treatment strategies.
Background Despite our previous findings that both total astragalus saponins (TAS) and hepatic AAV8. Numb -Exon3 overexpression (AAV8. Numb -Ex3 OE ) are effective against cholestatic liver fibrosis (CLF), the synergistic effect and mechanism of their combination remain unknown. This study was designed to investigate this combination therapy and elucidate its underlying molecular mechanisms. Methods A rat model of CLF was induced by bile duct ligation and subsequently treated with combination therapy. Evaluations included serum biochemical parameters, liver histopathology, hepatic hydroxyproline (Hyp) content, expression levels of key molecules in the Notch signaling pathway, hepatic progenitor cells (HPCs) differentiation, ductular reaction (DR), and liver regeneration. In vitro , WB-F344 cells were induced toward a cholangiocyte-like phenotype, and the influence of TAS on HPCs differentiation was assessed following LV. Numb -Ex3 transfection. Results The combination therapy more effectively improved serum biochemistry, reduced hepatic inflammation and collagen deposition, and lowered hepatic Hyp content compared to TAS or AAV8. Numb -Ex3 OE monotherapy. Mechanistically, the combination therapy further suppressed differentiation of HPCs into cholangiocytes and inhibited DR, while promoting HPC-to-hepatocyte differentiation and enhancing liver regeneration. Conclusion The combination of TAS and AAV8. Numb -Ex3 OE exerts a synergistic anti-fibrotic effect in CLF by redirecting HPCs differentiation fate. These findings provide experimental support for the development of novel combinatorial strategies against liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Zong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: